All In Biotech

Drug Trial Radar · NCT00242489

Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)

A Placebo-Controlled, Parallel-Group, Double-Blind Study to Assess Safety and to Define the Clinically Effective Dose Range of MK0663 in Patients With Osteoarthritis of the Knee, Followed by a Double-Blind, Active-Comparator-Controlled Extension.

Last checked: Nov 19, 2026Latest source record: Feb 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,167 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,167

Actual

Start

Jun 1998

Primary completion

Feb 1999

Study completion Jul 2002

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Oct 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of etoricoxib in the treatment of osteoarthritis of the knee.

Conditions

  • Osteoarthritis

Interventions

  • MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)Drug

  • Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeksDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. WOMAC Pain Subscale, Investigator Global Assessment of Disease Status, and Patient Global Assessment of Response to Therapy (not a primary endpoint in extension periods)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.